RPG Life Sciences Q2 revenue rises 16.5% above ₹200 crore
In short
RPG Life Sciences reported Q2 revenue up 16.5% and said sales crossed ₹200 crore. Profit fell to ₹28.22 crore, and margins were weaker than before.
This matters because sales are growing but profits are not keeping pace. The report says last year had an exceptional gain of ₹11.22 crore, but it does not explain the full reason for the weaker margin.
What the reporting says
RPG Life Sciences reported Q2 revenue growth of 16.5% to above ₹200 crore, while margin weakened and profit fell year on year to ₹28.22 crore. The publisher-supplied summary says the profit comparison was affected partly by an exceptional gain of ₹11.22 crore in the same quarter last year. Domestic formulations grew 11.6%, but the report does not state the main cause of the margin pressure.
Why it matters
RPG Life Sciences reported Q2 revenue rising 16.5% to above ₹200 crore, while profit fell year on year to ₹28.22 crore and margins weakened. Domestic formulations grew 11.6%, and the company was described as the fourth-fastest growing in the Indian pharmaceutical market. The available reporting does not give the detailed margin drivers, but the quarter appears mixed: stronger sales, weaker profitability.